Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

115.21
-0.4900-0.42%
Volume:204.83K
Turnover:23.69M
Market Cap:12.45B
PE:253.96
High:116.97
Open:114.42
Low:113.20
Close:115.70
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.42
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.65
PE(LYR):140.50

Loading ...

Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price

Simply Wall St.
·
May 02

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 02

Stock Track | Corcept Therapeutics Soars 5.33% Intraday After Piper Sandler Raises Price Target to $88

Stock Track
·
May 01

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

TIPRANKS
·
May 01

U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International

Reuters
·
May 01

Corcept Therapeutics Inc : Piper Sandler Raises Target Price to $88 From $73

THOMSON REUTERS
·
May 01

Corcept Therapeutics Swings to Loss, Says ALS Drug Didn't Meet Primary Endpoint

Dow Jones
·
May 01

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

TIPRANKS
·
May 01

Corcept Q1 revenue rises but misses analyst estimates

Reuters
·
May 01

Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30

MT Newswires Live
·
May 01

GUIDANCE: (CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M

MT Newswires Live
·
May 01

Corcept Q1 turns to USD 31.8 million net loss; revenue rises to USD 164.9 million

Reuters
·
May 01

Corcept says Phase 2 ALS study shows 87% lower death risk with dazucorilant

Reuters
·
May 01

Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate

Benzinga Earnings
·
May 01

BRIEF-Corcept Therapeutics Q1 EPS USD -0.3

Reuters
·
May 01

Corcept Therapeutics Inc - Dazucorilant Shows 87% Reduction in Risk of Death Versus Placebo

THOMSON REUTERS
·
May 01

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 01

Corcept Therapeutics Outlook FY Revenue USD 950-1,050 Million

THOMSON REUTERS
·
May 01

Corcept Therapeutics Inc - Expects Return to Profitability in Q2 2026

THOMSON REUTERS
·
May 01

A Look At Corcept Therapeutics (CORT) Valuation After Lifyorli’s FDA Approval And Upcoming ROSELLA Phase 3 Data

Simply Wall St.
·
Apr 26